ImmunityBio Q1 Sales Jump 168% to $44.2M; Reports $0.62 Loss, FDA Warning
IBRX•ImmunityBio posted Q1 sales of $44.21 million, a 168% increase driven by Anktiva unit growth, but reported a $0.62 per-share loss versus an expected $0.07 loss. The FDA issued a warning on unsupported Anktiva claims and a securities class action was filed as the company holds a current ratio of 6.67.
1. Q1 Financial Results
ImmunityBio recorded $44.21 million in Q1 revenue, marking a 168% increase from $16.52 million year-ago, fueled by higher Anktiva unit sales. The company posted a $0.62 per-share loss, compared with analysts’ expected $0.07 loss, reflecting higher operating expenses and research and development investments.
2. Regulatory and Legal Challenges
In April, the FDA issued a warning letter citing unsupported claims about Anktiva’s effectiveness, prompting review of the company’s promotional materials. A securities class action lawsuit was filed on behalf of investors who acquired shares between January and March 2026, alleging material misstatements tied to Anktiva disclosures.
3. Strong Liquidity Position
ImmunityBio holds a current ratio of 6.67, indicating the company has more than six times its short-term liabilities in liquid assets, and maintains minimal debt with a debt-to-equity ratio of –0.05. Its high price-to-sales ratio of 62.06 and negative price-to-earnings ratio of –10.23 reflect investor optimism despite ongoing losses.
